Abstract
Before the cloning of the CFTR gene in 1989, there were relatively few treatment options for the many phenotypes associated with cystic fibrosis (CF). The advancement of research in areas such as immunology, molecular biology and pharmacology have provided new insights into the mechanism and evolution of CF. More than 40 systematic clinical trials evaluating new therapies for CF are presently registered with the NIH. A great deal of effort is focused on the main cause of mortality: chronic and persistent lung infections. Intestinal malabsorption, pancreatic insufficiency, reduced bone mineral density and reproductive abnormalities are other manifestations of this disease that have been targeted by innovated treatments which are giving renewed hope to CF patients and their families. The following review is a summary of the novel pharmaceutical approaches for the treatment of cystic fibrosis aimed at improving both the quality and the longevity of the lives of patients afflicted with this devastating disease.
Keywords: cystic fibrosis, clinical trials, novel treatments, lung, intestinal, bone density, reproductive abnormalities
Current Pharmaceutical Design
Title: Novel Pharmaceutical Approaches for Treating Patients with Cystic Fibrosis
Volume: 13 Issue: 31
Author(s): Z. Saeed, G. Wojewodka, D. Marion, C. Guilbault and D. Radzioch
Affiliation:
Keywords: cystic fibrosis, clinical trials, novel treatments, lung, intestinal, bone density, reproductive abnormalities
Abstract: Before the cloning of the CFTR gene in 1989, there were relatively few treatment options for the many phenotypes associated with cystic fibrosis (CF). The advancement of research in areas such as immunology, molecular biology and pharmacology have provided new insights into the mechanism and evolution of CF. More than 40 systematic clinical trials evaluating new therapies for CF are presently registered with the NIH. A great deal of effort is focused on the main cause of mortality: chronic and persistent lung infections. Intestinal malabsorption, pancreatic insufficiency, reduced bone mineral density and reproductive abnormalities are other manifestations of this disease that have been targeted by innovated treatments which are giving renewed hope to CF patients and their families. The following review is a summary of the novel pharmaceutical approaches for the treatment of cystic fibrosis aimed at improving both the quality and the longevity of the lives of patients afflicted with this devastating disease.
Export Options
About this article
Cite this article as:
Saeed Z., Wojewodka G., Marion D., Guilbault C. and Radzioch D., Novel Pharmaceutical Approaches for Treating Patients with Cystic Fibrosis, Current Pharmaceutical Design 2007; 13 (31) . https://dx.doi.org/10.2174/138161207782341268
DOI https://dx.doi.org/10.2174/138161207782341268 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Improving Sub-Unit Vaccine Efficacy Using Cytokines as more Specific Immune Inducing Adjuvants
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Microglia in Alzheimer’s Disease
Current Alzheimer Research Fabrication and Physicochemical and Medicinal Characterization of Nano Traditional Chinese Medicine
Recent Patents on Engineering Transition Metal-Based Prodrugs for Anticancer Drug Delivery
Current Medicinal Chemistry Dose HLA-B5, 7, 8, 27, and 51 Antigens Associated to Behcet's disease? A Study in Southwestern Iran
Current Rheumatology Reviews Relationship Between Hypertension and Atherosclerosis: From a Viewpoint of the Most Potent Vasoconstrictor Human Urotensin II
Current Hypertension Reviews Driving Neural Stem Cells Towards a Desired Phenotype
Current Stem Cell Research & Therapy The Heme Oxygenase System and Type-1 Diabetes
Current Pharmaceutical Design Adult and Embryonic Stem Cells in Cartilage Repair
Current Rheumatology Reviews Surface-Enhanced Laser Desorption/Ionization Mass Spectrometry for Biomarker Discovery in Cutaneous Melanoma
Current Proteomics Myeloid Derived Suppressor Cells and Their Role in Diseases
Current Medicinal Chemistry Role of Cytokines and Cytokine Therapy in Wound Healing and Fibrotic Diseases
Current Pharmaceutical Design Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Current Cancer Drug Targets Compounds From Celastraceae Targeting Cancer Pathways and Their Potential Application in Head and Neck Squamous Cell Carcinoma: A Review
Current Genomics The Heme Oxygenase System Selectively Modulates Proteins Implicated in Metabolism, Oxidative Stress and Inflammation in Spontaneously Hypertensive Rats
Current Pharmaceutical Design From Bone Marrow Transplantation to Cellular Therapies: Possible Therapeutic Strategies in Managing Autoimmune Disorders
Current Pharmaceutical Design Colloidal Carrier Systems for Transcutaneous Immunization
Current Drug Targets Glia: An Important Target for Anti-Inflammatory and Antidepressant Activity
Current Drug Targets Personalized Medicine in Psoriasis: Concept and Applications
Current Vascular Pharmacology Is Obesity a Disease of the Blood-Brain Barrier? Physiological, Pathological, and Evolutionary Considerations
Current Pharmaceutical Design